Intermittent Androgen Suppression for Prostate Cancer: Rationale and Clinical Experience

No abstract is available for this paper.

• Publication year

  1998

• Venue

  European Urology

• Publication date

  1998-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000052297PMID 9854195
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.

  1998cited by this paper
• Intermittent androgen suppression: rationale and clinical experience

  1998cited by this paper
• Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer.

  1997cited by this paper
• Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

  1997cited by this paper
• Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.

  1996cited by this paper
• Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study.

  1996cited by this paper
• Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.

  1995cited by this paper
• Effects of intermittent androgen suppression on androgen‐dependent tumors. Apoptosis and serum prostate‐specific antigen

  1993cited by this paper
• Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer

  1993cited by this paper
• The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.

  1992cited by this paper
• The endocrinology and treatment of prostate tumor progression.

  1987cited by this paper
• Intermittent endocrine therapy for advanced prostate cancer

  1986cited by this paper
• Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system.

  1982cited by this paper
• Hormonal control of growth and progression in tumors of Nb rats and a theory of action.

  1977cited by this paper
• The veterans administration cooperative urological research group's studies of cancer of the prostate

  1973cited by this paper

• Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

  2021cites this paper
• Anti-Tumor Effects of Ginsenoside 20(S)-Protopanaxadiol and 1,25-Dihydroxyvitamin D3 Combination in Castration Resistant Prostate Cancer

  2021cites this paper
• Management of Patients With Advanced Prostate Cancer: Establishment of Treatment Guidelines Through Prostate Cancer Summit (PCAS) 2016 Composed of Korean Prostate Cancer Experts

  2020cites this paper
• Preparation of Liposomal Sanguinarine and Study of Its Cytotoxic Effects against Prostate Cancer Cells

  2020cites this paper
• A review on Herbal Nanoparticles

  2018cites this paper
• Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network

  2018cites this paper
• Title Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer

  2017cites this paper
• Homepage: www.kup.at/urologie Online-Datenbank mit Autoren-und Stichwortsuche

  2017cites this paper
• Nanotechnology for enhanced bioactivity of bioactive phytomolecules

  2017cites this paper
• Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis

  2016cites this paper
• Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer

  2015cites this paper
• Dynamical Aspects of a Hybrid System Describing Intermittent Androgen Suppression Therapy of Prostate Cancer

  2015cites this paper
• Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

  2015cites this paper
• Environmental endocrine disruptors: Effects on the human male reproductive system

  2015cites this paper
• The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors

  2015cites this paper
• 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy.

  2015cites this paper
• Cytotoxic effect of s-petasin and iso-s-petasin on the proliferation of human prostate cancer cells.

  2015cites this paper
• Inhibition of Polo-like Kinase 1 (Plk1) Enhances the Antineoplastic Activity of Metformin in Prostate Cancer*

  2014cites this paper
• Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer

  2014cites this paper
• Intermittent Androgen Deprivation in the New Era: The Role of Urologist and Oncologist in a Multidisciplinary Team (MDT)

  2014cites this paper
• Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research

  2014cites this paper
• Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.

  2014cites this paper
• Molecular Mechanisms of Castrate Resistant Prostate Cancer

  2013cites this paper
• Current evidence about intermittent androgenic deprivation in prostate cancer

  2013cites this paper
• Pipernonaline from Piper longum Linn. induces ROS-mediated apoptosis in human prostate cancer PC-3 cells.

  2013cites this paper
• 5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models.

  2013cites this paper
• Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.

  2013cites this paper
• Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo

  2013cites this paper
• Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.

  2013cites this paper
• Salonen Intermittent versus Continuous Androgen Deprivation in Patients with Advanced Prostate Cancer

  2013cites this paper
• A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo

  2013cites this paper
• Adaptive Stress Response and AR Stability Castrate-Resistant Prostate Cancer Progression by Inhibiting Cotargeting Androgen Receptor and Clusterin Delays

  2013cites this paper
• Cancer Systems Biology

  2013cites this paper
• Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects.

  2013cites this paper
• Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.

  2013cites this paper
• Carbidopa abrogates L‐dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression

  2012cites this paper
• [Current evidence about intermittent androgenic deprivation in prostate cancer].

  2012cites this paper
• The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.

  2012cites this paper
• Androgen Receptor Drives Cellular Senescence

  2012cites this paper
• Landmarks in hormonal therapy for prostate cancer

  2012cites this paper
• Current evidence about intermittent androgenic deprivation in prostate cancer

  2012cites this paper
• Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.

  2011cites this paper
• Cancer Robustness and Therapy Strategies

  2011cites this paper
• Effect of luteinizing hormone-releasing hormone agonists on the testosterone levels and quality of life in patients with locally advanced and generalized prostate cancer

  2011cites this paper
• Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer

  2010cites this paper
• Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.

  2010cites this paper
• Mathematical modelling of prostate cancer growth and its application to hormone therapy

  2010cites this paper
• Inhibition of 5α‐reductase enhances testosterone‐induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice

  2010cites this paper
• Tumor-specific targeting using oncolytic herpes simplex virus type 1 for prostate cancer treatment

  2009cites this paper
• The effect of cyclin G associated kinase on androgen receptor function and prostate cancer progression

  2009cites this paper
• In vivo Knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors

  2009cites this paper
• Inhibition of human prostate cancer cells proliferation by a selective alpha1-adrenoceptor antagonist labedipinedilol-A involves cell cycle arrest and apoptosis.

  2009cites this paper
• Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation.

  2008cites this paper
• Anticancer and antiproliferative activity of natural brassinosteroids.

  2008cites this paper
• A Mathematical Model of Intermittent Androgen Suppression for Prostate Cancer

  2008cites this paper
• A nonlinear model with competition between prostate tumor cells and its application to intermittent androgen suppression therapy of prostate cancer.

  2008cites this paper
• Zalecenia dotyczące postępowania w raku gruczołu krokowego - konferencja okrągłego stołu

  2007cites this paper
• Employing the treatment‐free interval of intermittent androgen ablation to screen candidate prostate cancer therapies

  2007cites this paper
• Award Number: W81XWH-04-1-0220 TITLE: SANGUINARINE: A NOVEL AGENT AGAINST PROSTATE CANCER

  2007cites this paper
• MATHEMATICAL ENGINEERING TECHNICAL REPORTS A Mathematical Model of Intermittent Androgen Suppression Remedy for Prostate Cancer

  2006cites this paper
• PSA Bounces After Neoadjuvant Androgen Deprivation and External Beam Radiation: Impact on Definitions of Failure

  2006cites this paper
• Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.

  2006cites this paper
• 16TH INTERNATIONAL PROSTATE CANCER UPDATE Hormonal Therapy for Prostate Cancer

  2006cites this paper
• Hormonal therapy for prostate cancer.

  2006cites this paper
• Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.

  2006cites this paper
• Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells

  2006cites this paper
• PSA bounces after neoadjuvant androgen deprivation and external beam radiation: impact on definitions of failure.

  2005cites this paper
• Immediate Treatment after PSA Progression

  2005cites this paper
• Adjuvante medikamentöse Therapie des Prostatakarzinoms

  2005cites this paper
• The association of infiltrating lymphocytes in androgen ablation induced apoptosis of prostate tumours

  2005cites this paper
• Die intermittierende Hormonsuppression beim Prostatakarzinom

  2005cites this paper
• Complications of androgen-deprivation therapy in men with prostate cancer

  2005cites this paper
• Hormonal Therapy in Prostate Cancer: Historical Approaches

  2004cites this paper
• Complications of androgen deprivation therapy in men with prostate cancer

  2004cites this paper
• Hormonal therapy in prostate cancer: historical approaches.

  2004cites this paper
• Rôle de la protéine tyrosine kinase Fer dans le cancer de la prostate

  2004cites this paper
• Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery.

  2004cites this paper
• PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium.

  2003cites this paper
• Prostate cancer and bone metastases: medical treatment.

  2003cites this paper
• A 10-year clinical experience with intermittent hormonal therapy for prostate cancer.

  2003cites this paper
• Tea Beverage in Chemoprevention of Prostate Cancer: A Mini-Review

  2003cites this paper
• Prostate Cancer Update: Advanced Disease

  2003influential citation
• Hormonal therapy: historical perspective to future directions.

  2003cites this paper
• Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003.

  2003cites this paper
• Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?

  2003cites this paper
• Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant.

  2003cites this paper
• Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.

  2002cites this paper
• Highlights of contemporary issues in the medical management of prostate cancer.

  2002cites this paper
• Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma

  2002cites this paper
• LEUPRORELIN ACETATE IN PROSTATE CANCER: A EUROPEAN UPDATE

  2002cites this paper
• Controversies in the systemic management of patients with evidence of biochemical failure following radical prostatectomy.

  2002cites this paper
• Gene expression profiling of the human prostate androgen response program.

  2002cites this paper
• Hormonal treatment for prostate cancer

  2001cites this paper
• Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

  2001cites this paper
• Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer.

  2001cites this paper
• Systemic treatment and new developments in advanced prostate cancer.

  2001cites this paper
• Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study.

  2001cites this paper
• Trends in Hormonal Management of Prostate Cancer:: A Population-Based Study in Ontario

  2001cites this paper
• Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy.

  2001cites this paper
• Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells

  2001cites this paper